1. Brummett BH, Babyak MA, Siegler IC, et al. Systolic blood pressure, socioeconomic status, and biobehavioral risk factors in a nationally representative US young adult sample. Hypertension 2011;58:161-166.
2. May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular disease risk factors among US adolescents, 1999-2008. Pediatrics 2012;129:1035-1041.
3. Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124:1046-1058.
4. Glasser SP, Judd S, Basile J, et al. Prehypertension, racial prevalence and its association with risk factors: analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Am J Hypertens 2011;24:194-199.
5. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-2050.
6. Morris AA, Patel RS, Binongo JNG, et al. Racial differences in arterial stiffness and microcirculatory function between black and white Americans. J Am Heart Assoc 2013;2:e002154.
8. Kozor R, Grieve SM, Buchholz S, et al. Regular cocaine use is associated with increased systolic blood pressure, aortic stiffness and left ventricular mass in young otherwise healthy individuals. PloS One 2014;9:e89710.
9. Townsend RR, Wilkinson IB, Schiffrin EL, et al. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: a scientific statement from the American Heart Association. Hypertension 2015;66:698-722.
10. Petoumenos K, Worm S, Reiss P, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med 2011;12:412-421.
11. Medina-Torne S, Ganesan A, Barahona I, et al. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Physicians AIDS Care (Chic) 2012;11:20-25.
12. Monroe AK, Chander G, Moore RD. Control of medical comorbidities in individuals with HIV. J Acquir Immune Defic Syndr 2011;58:458-462.
13. Manner IW, Baekken M, Kvale D, et al. Markers of microbial translocation predict hypertension in HIV-infected individuals. HIV Med 2013;14:354-361.
14. Jones DL, Rodriguez VJ, Alcaide ML, et al. Subclinical atherosclerosis among young and middle-aged adults using carotid intima-media thickness measurements. South Med J 2017;110:733-737.
15. Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sport Exer 2003;35:1381-1395.
16. MacAuley D, Bauman AE, Frémont P. Exercise: not a miracle cure, just good medicine. Br J Sports Med 2016;50:1107-1108.
17. Gans KM, Risica PM, Wylie-Rosett J, et al. Development and evaluation of the nutrition component of the Rapid Eating and Activity Assessment for Patients (REAP): a new tool for primary care providers. J Nutr Educ Behav 2006;38:286-292.
18. Radloff LS. The CES-D scale a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
19. First MB, Williams JBW, Gibbon M. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version. Washington, DC:American Psychiatric Association;1997.
20. SPSS version 24. Armonk, NY: IBM SPSS Statistics.
21. Ersche KD, Stochl J, Woodward JM, et al. The skinny on cocaine: insights into eating behavior and body weight in cocaine-dependent men. Appetite 2013;71:75-80.
22. Mooney ME, Herin DV, Schmitz JM, et al. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2009;101:34-41.
23. Grunfeld C, Pang M, Shimizu L, et al. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992;55:455-460.
24. Macallan D, Noble C, Baldwin C, et al. Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. Am J Clin Nutr 1993;58:417-424.
25. Rodondi N, Pletcher MJ, Liu K, et al. Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA study). Am J Cardiol 2006;98:478-484.
26. Beires MT, Silva-Pinto A, Santos AC, et al. Visceral adipose tissue and carotid intima-media thickness in HIV-infected patients undergoing cART: a prospective cohort study. BMC Infect Dis 2018;18:32.
27. Weiner SD, Ahmed HN, Jin Z, et al. Systemic inflammation and brachial artery endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). Heart 2014;100:862-866.
28. Addai AB, Pandhare J, Paromov V, et al. Cocaine modulates HIV-1 integration in primary CD4+ T cells: implications in HIV-1 pathogenesis in drug-abusing patients. J Leukoc Biol 2015;97:779-790.
29. Pandhare J, Addai AB, Mantri CK, et al. Cocaine enhances HIV-1-induced CD4(+) T-cell apoptosis: implications in disease progression in cocaine-abusing HIV-1 patients. Am J Pathol 2014;184:927-936.
30. Napuri J, Pilakka-Kanthikeel S, Raymond A, et al. Cocaine enhances HIV-1 infectivity in monocyte derived dendritic cells by suppressing microRNA-155. PLoS One 2013;8:e83682.
31. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999;99:1165-1172.
32. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001;345:351-358.
33. Sharma J, Rathnayaka N, Green C, et al. Bradycardia as a marker of chronic cocaine use: a novel cardiovascular finding. Behav Med 2016;42:1-8.
34. Bhargava S, Arora RR. Cocaine and cardiovascular complications. Am J Ther 2011;18:e95-e100.
35. Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-129.
36. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action, Concerted Action on SeroConversion to AIDS and Death in Europe. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000;355:1131-1137.
37. Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA 2009;302:401-411.
38. Lee DC, Sui X, Church TS, et al. Changes in fitness and fatness on the development of cardiovascular disease risk factors hypertension, metabolic syndrome, and hypercholesterolemia. J Am Coll Cardiol 2012;59:665-672.
39. Booth JN 3rd, Li J, Zhang L, et al. Trends in prehypertension and hypertension risk factors in US adults: 1999-2012. Hypertension 2017;70:275-284.
40. Stergiou G, Margetaki A, Boubouchairopoulou N, et al. Hypertension and other modifiable cardiovascular risk factors in Greece: interim analysis of the EMENO National Epidemiology Study. J Hypertens 2016;34:e235.
41. Ximenes RA, Lacerda HR, Miranda-Filho DB, et al. Comparison between potential risk factors for cardiovascular disease in people living with HIV/AIDS in areas of Brazil. J Infect Dev Ctries 2015;9:988-996.
42. Bauer S, Wa Mwanza M, Chilengi R, et al. Awareness and management of elevated blood pressure among human immunodeficiency virus-infected adults receiving antiretroviral therapy in urban Zambia: a call to action. Glob Health Action 2017;10:1359923.
43. Chatterton-Kirchmeier S, Camacho-Gonzalez AF, McCracken CE, et al. Increased prevalence of elevated blood pressures in HIV-infected children, adolescents and young adults. Pediatr Infect Dis J 2015;34:610-614.
44. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation 2010;122:2558-2569.